Results 111 to 120 of about 38,006 (217)

Realizing Benefits of First-in-Class Generic Entry-The Case of SGLT2 Inhibitors. [PDF]

Clin Pharmacol Ther
Gondi S, Kesselheim AS, Rome BN.
europepmc   +1 more source

Clinical characteristics and in‐hospital mortality among insulin pump users with acute coronary syndrome in the predominantly open‐loop era: A UK‐wide MINAP registry analysis

Diabetic Medicine, EarlyView.
Abstract Background We compared characteristics of adults with insulin‐treated diabetes using continuous subcutaneous insulin infusion (CSII) versus multiple daily insulin injections (MDI) during admission with acute coronary syndrome (ACS) and identified factors associated with in‐hospital mortality among CSII users.
Harshal Deshmukh, Moosa Shaikh, Emma G. Wilmot, Eric Kilpatrick, Sudipta Chattopadhyay, Thozhukat Sathyapalan, Joseph John   +6 more
wiley   +1 more source

It's a game changer in terms of diabetic management’: A qualitative study of adolescents' and parents' experiences of a 6‐month trial of continuous glucose monitoring in type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando, Alexia S. Peña, Ashlee King, Melissa Oxlad   +3 more
wiley   +1 more source

SGLT2 Inhibitors in Nephrolithiasis: Emerging Evidence and What Urologists Need to Know. [PDF]

Med Sci (Basel)
Ivănuță M, Puia D, Ivănuță AM, Haută A, Nistor I, Pricop C.   +5 more
europepmc   +1 more source

Multisystem developmental abnormalities and insulin resistance in ADTKD‐HNF1B with the p.E105K variant: A clinical conundrum

Diabetic Medicine, EarlyView.
Abstract Aims HNF1B variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD‐HNF1B), but the phenotypic spectrum of variants of uncertain significance (VUS) remains incompletely defined. We aimed to characterise the multisystem phenotype associated with the HNF1B p.E105K variant and to examine the mechanism underlying insulin ...
YunZe Wang, KangChun Xu, PengFei Liu, Bin Wang, Yan Yang, ShanZhai Wei   +5 more
wiley   +1 more source

Preliminary Evaluation of SGLT2 Inhibitors in Human Bladder Cancer T24 Cells. [PDF]

Biomedicines
Szachniewicz M, Baran M, Gagat M, Hałas-Wiśniewska M.   +3 more
europepmc   +1 more source

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden, Pam Leblanc, Chloe Parezanovic, Vikas S. Sridhar, Bruce A. Perkins, David Z. Cherney, David J. T. Campbell   +6 more
wiley   +1 more source

Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. Reply. [PDF]

J Clin Invest
Abdualkader AM, Al Batran R.
europepmc   +1 more source

The role of sex and ethnicity in the variability of estimated glomerular filtration rate (eGFR) in people with type 1 diabetes

Diabetic Medicine, EarlyView.
Exploring Sex and Ethnicity Differences in eGFR for People with Type I Diabetes. Abstract Aims To examine sex‐based differences in estimated glomerular filtration rate (eGFR) trajectories for people with type 1 diabetes (T1D) over 10 years and to test the hypothesis that sex and ethnicity interaction predicts eGFR decline.
Salma Ayis, Murat Ozdede, Luigi Gnudi, Thamer Alobaid, Panagiotis Pavlou, Anastasios Mangelis, Nikolaos Fountoulakis, Aicha Goubar, Janaka Karalliedde   +8 more
wiley   +1 more source

Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies? [PDF]

Front Stroke
Ihle-Hansen H, Ihle-Hansen H, Blauenfeldt RA, Dawson J, Diederichsen SZ, Hagberg G.   +5 more
europepmc   +1 more source